Literature DB >> 9130046

Activation and regulation of human cytomegalovirus early genes.

D H Spector1.   

Abstract

The multiple pathogenic effects of human cytomegalovirus (HCMV) result from a complex interplay of viral gene products and induced and repressed cellular functions. HCMV immediate early and early gene expression clearly play a pivotal role in this scheme. I describe here work directed at elucidating the sequence requirements and trans-acting factors necessary for the activation and regulation of HCMV early genes. The focus is on three transcription units which are all activated at early times, but exemplify differential patterns of expression as the infection progresses, including: the major 2.7- and 1.2-kb transcripts encoded by the repeat bounding of the long unique segment of the genome, and a family of differentially spliced transcripts (originally designated the 2.2-kb RNAs-ORF UL112-113) which encode four proteins that are required in the transient complementation assay for HCMV DNA replication. Selected other early genes which illustrate alternative mechanisms of control are also discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9130046     DOI: 10.1159/000150507

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  45 in total

1.  A strong negative transcriptional regulatory region between the human cytomegalovirus UL127 gene and the major immediate-early enhancer.

Authors:  C A Lundquist; J L Meier; M F Stinski
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  UL82 virion protein activates expression of immediate early viral genes in human cytomegalovirus-infected cells.

Authors:  W A Bresnahan; T E Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

3.  Random, asynchronous, and asymmetric transcriptional activity of enhancer-flanking major immediate-early genes ie1/3 and ie2 during murine cytomegalovirus latency in the lungs.

Authors:  N K Grzimek; D Dreis; S Schmalz; M J Reddehase
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  In vivo replication of recombinant murine cytomegalovirus driven by the paralogous major immediate-early promoter-enhancer of human cytomegalovirus.

Authors:  N K Grzimek; J Podlech; H P Steffens; R Holtappels; S Schmalz; M J Reddehase
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  Role of regulatory elements and the MAPK/ERK or p38 MAPK pathways for activation of human cytomegalovirus gene expression.

Authors:  Jiping Chen; Mark F Stinski
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  The human cytomegalovirus major immediate-early enhancer determines the efficiency of immediate-early gene transcription and viral replication in permissive cells at low multiplicity of infection.

Authors:  Hiroki Isomura; Mark F Stinski
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  Activation of transcription of the human cytomegalovirus early UL4 promoter by the Ets transcription factor binding element.

Authors:  J Chen; M F Stinski
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

8.  Coding potential of laboratory and clinical strains of human cytomegalovirus.

Authors:  Eain Murphy; Dong Yu; Jane Grimwood; Jeremy Schmutz; Mark Dickson; Michael A Jarvis; Gabriele Hahn; Jay A Nelson; Richard M Myers; Thomas E Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

Review 9.  Noncoding RNPs of viral origin.

Authors:  Joan Steitz; Sumit Borah; Demian Cazalla; Victor Fok; Robin Lytle; Rachel Mitton-Fry; Kasandra Riley; Tasleem Samji
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-03-01       Impact factor: 10.005

10.  A short cis-acting motif in the M112-113 promoter region is essential for IE3 to activate M112-113 gene expression and is important for murine cytomegalovirus replication.

Authors:  Kareni J Perez; Francisco Puerta Martínez; Ruth Cosme-Cruz; Neysa M Perez-Crespo; Qiyi Tang
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.